Bill Nelson, director of Johns Hopkins Kimmel Cancer Center, is conducting a series of interviews commemorating the cancer center’s 50th anniversary.
Johns Hopkins Medicine received a $35 million gift from researcher, philanthropist, and race car driver Theodore Giovanis. Scientists will use the gift to study how cancer metastasizes through the body.
SpaceMarkers, a machine learning software developed by researchers at the Johns Hopkins Convergence Institute and the Johns Hopkins Kimmel Cancer Center, can identify molecular interactions among distinct types of cells in and around a tumor, according to a study published in Cell Systems.
In a phase II, single-arm study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, patients with resectable non-small cell lung cancer who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.
Three-year (36.5 months minimum; 44.0 months median) follow-up results from the phase III CheckMate -9ER trial demonstrated sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma, according to Bristol Myers Squibb and Exelixis Inc.
Investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that a subset of mutations within the overall tumor mutation burden, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors continuously visible to the immune system and predisposing them to respond to immunotherapy.
In a study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers driven by overexpression of the mechanistic target of rapamycin complex 1 signaling pathway with loss of the tuberous sclerosis complex tumor suppressor gene.
An artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now detected more than 80% of liver cancers in a new study of 724 people.
Researchers at Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy successfully trained a machine learning algorithm to predict, in hindsight, which patients with melanoma would respond to treatment and which would not, in a small study.
Research findings from the Johns Hopkins Kimmel Cancer Center show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.